- Conditions
- Adenocarcinoma, Breast Diseases, Breast Neoplasms, +38 more
- Locations
-
- Peter MacCallum Cancer Centre Melbourne, Australia
- UNSW Sydney, St Vincent's Hospital Sydney Sydney, Australia
- Centre Jean Perrin Clermont-Ferrand, France
- Centre Georges François Leclerc Dijon, France
Clinical trial condition
Triple Negative Breast Cancer (TNBC)
Explore clinical trials studying Triple Negative Breast Cancer (TNBC). Study availability and eligibility vary by location and protocol.
50 public trials
26 recruiting studies
Triple Negative Breast Cancer (TNBC) trial results
NCT05107674
- Conditions
- Adenoma, Adnexal Diseases, Breast Diseases, +75 more
- Locations
-
- City of Hope Duarte, California, United States
- University of Southern California Los Angeles, California, United States
- University of California, San Francisco San Francisco, California, United States
- University of Colorado School of Medicine Aurora, Colorado, United States
- Conditions
- Breast Diseases, Breast Neoplasm, Breast Neoplasms, +7 more
- Locations
-
- Royal Bournemouth Hospital Bournemouth, Dorset, United Kingdom
- King's College Hospital London, England, United Kingdom
- Christie Hospital NHS Trust Manchester, England, United Kingdom
- Velindre Cancer Center at Velinde Hospital Cardiff, Wales, United Kingdom
NCT06476119
- Conditions
- Breast Cancer Stage I, Breast Diseases, Breast Neoplasms, +6 more
- Locations
-
- Zuyderland Medisch Centrum Sittard-Geleen, Limburg, Netherlands
- Medical spectrum Twente Enschede, Overijssel, Netherlands
- Noordwest Ziekenhuisgroep Alkmaar, Netherlands
- Flevoziekenhuis Almere Stad, Netherlands
NCT06880029
- Conditions
- Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
- Locations
-
- Centro Hospitalar Vila Nova de Gaia/Espinho Vila Nova de Gaia, Região, Portugal
NCT06636981
- Conditions
- Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
- Fudan University Shanghai Cancer Center Shanghai, China
Enrolling by Invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003
- Conditions
- Adenocarcinoma, Breast Diseases, Breast Neoplasms, +54 more
- Locations
-
- UCSF Medical Center San Francisco, California, United States
- Yale Cancer Center New Haven, Connecticut, United States
- START Midwest Grand Rapids, Michigan, United States
- Memorial Sloan Kettering Cancer Center New York, United States
Enrolling by Invitation
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
NCT06885424
- Conditions
- Adenocarcinoma, Adenoma, Adnexal Diseases, +67 more
- Locations
-
- Banner Health Gilbert, Arizona, United States
- Mayo Clinic Rochester, Minnesota, United States
- NYU Langone Medical Center New York, United States
NCT07545122
- Conditions
- Breast Diseases, Breast Neoplasms, Colonic Diseases, +16 more
- Locations
-
- Tasman Oncology Research Gold Coast, Queensland, Australia
- Calvary Mater Hospital Newcastle Newcastle, Queensland, Australia
- Linear Clinical Research Perth, Western Australia, Australia
Not Yet Recruiting
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC
NCT07669610
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
- Locations
-
Not specified